How do clinicians screen for active pelvic or vulvar malignancies prior to administering exosome biostimulation therapy
Cancer safety Screening Caution Women’s Health Clinic FAQ How do clinicians screen for active pelvic or vulvar malignancies prior to administering exosome biostimulation therapy Exosome safety…
What is the biological risk of exosome signalling upregulating angiogenesis in undetected pre-cancerous lesions (e.g., VIN or CIN)
Cancer safety Screening Caution Women’s Health Clinic FAQ What is the biological risk of exosome signalling upregulating angiogenesis in undetected pre-cancerous lesions (e.g., VIN or CIN)…
How do regulatory bodies (e.g., MHRA, FDA) classify cell-free extracellular vesicle products versus human cell and tissue products
Regulation Traceability Consent Women’s Health Clinic FAQ How do regulatory bodies (e.g., MHRA, FDA) classify cell-free extracellular vesicle products versus human cell and tissue products Regulatory…
Can exosome therapy trigger systemic HLA sensitisation or alloimmune reactions in immunocompromised hosts
Immune risk Specialist review Suitability Women’s Health Clinic FAQ Can exosome therapy trigger systemic HLA sensitisation or alloimmune reactions in immunocompromised hosts Autoimmune disease, immunosuppression and…
What is the clinical protocol if a patient experiences an acute, localised type-I hypersensitivity reaction to a reconstituted exosome diluent
Immune safety Allergy Escalation Women’s Health Clinic FAQ What is the clinical protocol if a patient experiences an acute, localised type-I hypersensitivity reaction to a reconstituted…
How does the absence of MHC Class I and Class II proteins on purified exosomes minimise the risk of host graft reaction
Immune safety Allergy Escalation Women’s Health Clinic FAQ How does the absence of MHC Class I and Class II proteins on purified exosomes minimise the risk…
What safety precautions apply when reconstituting lyophilised exosome powders with preservative-free normal saline
Handling Stability Governance Women’s Health Clinic FAQ What safety precautions apply when reconstituting lyophilised exosome powders with preservative-free normal saline Handling and reconstitution topics should be…
How do clinicians evaluate donor screening and tissue sourcing protocols (e.g., FDA-compliant human umbilical cord tissue) for safety
Regulation Traceability Consent Women’s Health Clinic FAQ How do clinicians evaluate donor screening and tissue sourcing protocols (e.g., FDA-compliant human umbilical cord tissue) for safety Regulatory…
What is the risk of localised infection or micro-abscess formation when injecting exosomes into compromised or ulcerated mucosa
Infection Mucosa Deferral Women’s Health Clinic FAQ What is the risk of localised infection or micro-abscess formation when injecting exosomes into compromised or ulcerated mucosa Active…
Can exosomes be safely administered to patients actively taking systemic immunosuppressive or biologic therapies
Immune risk Specialist review Suitability Women’s Health Clinic FAQ Can exosomes be safely administered to patients actively taking systemic immunosuppressive or biologic therapies Autoimmune disease, immunosuppression…
Still not sure where to start?
Browse the wider treatment pages or book a free consultation so we can help you find the most relevant next step.
